Last reviewed · How we verify
Belimumab for IV
At a glance
| Generic name | Belimumab for IV |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe) (PHASE1)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- Belimumab With Rituximab for Primary Membranous Nephropathy (PHASE2)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- BENLYSTA® Special Drug Use Investigation
- Belimumab in Idiopathic Inflammatory Myositis (PHASE2, PHASE3)
- CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients (PHASE2)
- Rituximab and Belimumab Combination Therapy in PR3 Vasculitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |